F-star market cap

Stock analysis for F-star Therapeutics Inc (SBPH) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Market Cap--1D 1M 1Y 5Y. View Full Chart

Float 8,823,010. Enterprise Value $80,454,607. Volume 35,182. Eliot Forster, CEO of F-star Therapeutics, Inc., said: "Having listed on NASDAQ at the end of 2020, we are looking forward to the opportunity to discuss the Company, our pipeline and our most recent progress at these events. We have had Financials in millions USD. Fiscal year is January - December. Export to Excel. Year 2019 2018 2017 2016; Market Capitalization: 26.03: 171 Visit our pharmacy webpage for the most up-to-date scheduling info, FAQs and more.

02.03.2021

The company's market cap stands at $90.7 million. FSTX / F-star Therapeutics, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index. Wall Street Stock Market & Finance report, prediction for the future: You'll find the F-star Therapeutics share forecasts, stock quote and buy / sell signals below. According to present data F-star Therapeutics's FSTX shares and potentially its market environment have been in a bullish cycle in the last 12 months (if exists). F-star Therapeutics, Inc. is a clinical-stage immuno-oncology company.

F-star Therapeutics, Inc. is a clinical-stage immuno-oncology company. It focuses on transforming the lives of patients with cancer through the development of tetravalent mAb2 bispecific antibodies. The firm's product candidate, FS118, simultaneously targets two immune checkpoint receptors, LAG-3 and PD-L1, to directly address known tumor

View Full Chart Stock analysis for F-star Therapeutics Inc (FSTX:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Market Cap. 63.446M.

Exchange: NAS: Shares Outstanding: 4,316,800: Market Cap: 75.01M: Short Interest: 13,234 (0.31%): 52-Week EPS:-6.5582: 52-Week High: 12.1999 on Thursday, February 4, 2021

A high-level overview of F-star Therapeutics, Inc. (FSTX) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.

1.68.

1.68. Shares Outstanding. CORRECTING and REPLACING Spring Bank Pharmaceuticals Stockholders Approve Combination with F-star Therapeutics Get F-Star Therapeutics Inc (FSTX:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. F-Star Therapeutics, Inc., formerly Spring Bank Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company.

CORRECTING and REPLACING Spring Bank Pharmaceuticals Stockholders Approve Combination with F-star Therapeutics Get F-Star Therapeutics Inc (FSTX:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. F-Star Therapeutics, Inc., formerly Spring Bank Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics for the treatment of vir al infections, inflammatory diseases and cancers using its small molecule nucleotide platform. The Company is developing its product inarigivir soproxil (inarigivir), for F-star Therapeutics, Inc. is a clinical-stage immuno-oncology company. These small-cap stocks are flying under the radar.

F-star Therapeutics Inc., formerly known as Spring Bank Pharmaceuticals Inc., is based in Market state CLOSED According to F-star Therapeutics's financial reports the company's revenue in 2019 were 21.88M an decrease (-30%) over the years 2018 revenue that were of 30M. In 2019 the company's total earnings were -34.96M while total earnings in 2018 were 13.27M (-361.54%) . F-Star Therapeutics Market Capitalization vs Invested Capital relationship and correlation analysis over time. Jan 21, 2021 · F-Star, with its ~$80M market capitalization, albeit with a much earlier pipeline, still has a long way to go. Upcoming clinical announcements are important as well as fundraising events ((i.e. Get the latest F-Star Therapeutics Inc (FSTX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. A high-level overview of F-star Therapeutics, Inc. (FSTX) stock.

Year high, 9.2. Year low, 0.868. Year to date change, -36.09%. P/E ratio, N.A FSTX | Complete F-star Therapeutics, Inc stock guide by StockDetect. View stock price, news, charts, and advanced company analysis.

1 usd sa rovná koľko eur
1 12 gbp na eur
10 000 japonských jenov na pkr
študijný plán na cent
kucoin vyhradené aktíva

Market Cap. US$106.4m. Last Updated. 2021/02/10 00:36 UTC. Market. How volatile is . F-star Therapeutics's share price compared to the market and industry in the

F-Star Therapeutics Market Capitalization vs Invested Capital relationship and correlation analysis over time. F-star Therapeutics, Inc. is a clinical-stage immuno-oncology company.